How CDMO Pricing Works: Cost, Competition, And Strategic Pricing Decisions

If you've ever compared CDMO quotes for the same product and felt blindsided by a 2x or 3x price gap, you're not imagining things. According to George Ntortas and Kyriakos Kansos of Fuliginous Management Consulting, these differences are entirely rational once you understand what's actually driving them.

The core problem: most CDMOs rely exclusively on cost-plus pricing, which ignores two critical inputs — what your customer can actually afford to pay, and what the broader market looks like. The playbook introduces a three-element framework balancing cost-plus, market-minus, and competitive benchmark pricing.

Capacity utilization turns out to be the single biggest price driver. Two CDMOs sharing identical annual fixed costs of €200,000 and the same machine hours can produce fixed cost hourly rates of €38.10 versus €71.40 — simply because one runs at 75% utilization and the other at 40%. That's an 87% difference before direct costs or margin even enter the picture.

The Themistocles versus Xerxes case study makes this concrete: same product, same direct costs, final quotes of €25 versus €65.53 per thousand tablets. Neither is wrong. They're just in different business situations with different strategic priorities.

On the buy side, you'll learn to work backward from pharmacy prices to estimate customer margins, understand how therapeutic area and patent status affect willingness to pay, and calculate total cost of ownership rather than unit price alone.

Download now to stop being surprised by CDMO pricing and start asking the questions that actually matter.